Hepatic encephalopathy (HE) is a neuropsychiatric syndrome due to hepatic dysfunction and porto-systemic shunting of the intestinal blood. Cirrhosis is the most frequent liver disease causing HE. On most occasions, HE appears due to a superimposed precipitating factor (gastrointestinal bleeding, infections, renal and electrolyte disturbances, etc.). Ammonia produced in colon by intestinal bacteria is the main toxic substance implicated in the pathogenesis of HE. Other mechanisms, such as changes in the GABA-benzodiazepine system, accumulation of manganese into the basal ganglia of the brain, changes in blood-brain barrier and neurotransmission disturbances are also present. Clinical manifestations of HE may vary widely, from minimal neurologic changes, only detected with specific tests, to deep coma. Treatment of HE should be directed to controlling the precipitating factors, as well as therapies aimed at correcting the above-mentioned pathophysiological changes, mainly reduction of blood ammonia levels. Artificial liver support systems may play a role in the future. Liver transplantation should be evaluated as a definitive therapy in all cases of HE.

Journal Section:
Paper
Keywords:
Hepatic encephalopathy, Pathophysiology, Cirrhosis
1.
Córdoba J, Blei AT: Hepatic encephalopathy; in Schiff ER, Sorrell MF, Maddrey WC (eds): Schiff’s Diseases of the Liver. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 595–623.
2.
Ferenci P, Lockwood A, Mullen K, Terter R, Weissenborn K, Blei AT et al: Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification. Final Report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna 1998. Hepatology 2002;35:716–721.
3.
Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235–244.
[PubMed]
https://doi.org/10.1055%2Fs-2007-1007236
4.
Jones EA: Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002;17:275–281.
[PubMed]
https://doi.org/10.1023%2FA%3A1021949616422
5.
Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S: Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035–1038.
[PubMed]
https://doi.org/10.1016%2FS0168-8278%2800%2980110-5
6.
Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P et al: Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000;31:30–34.
[PubMed]
https://doi.org/10.1002%2Fhep.510310107
7.
Lockwood AH, McDonald JM, Rieman RE, Gelbard AS, Laughlin JS, Duffy TE et al: The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979;63:449–460.
[PubMed]
https://doi.org/10.1172%2FJCI109322
8.
Watanabe A, Takei N, Higashi T, Shiota T, Nakatsukasa H, Fujiwara M et al: Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy. Biochem Med 1984;32:225–231.
[PubMed]
https://doi.org/10.1016%2F0006-2944%2884%2990076-0
9.
Butterworth RF: Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 2000;13:721–727.
[PubMed]
https://doi.org/10.1097%2F00019052-200012000-00018
10.
Vasconez C, Elizalde JI, Llach J, Ginès A, de la Rosa C, Fernández RM et al: Helicobacter pylori, hyperammonemia and subclinical porto-systemic encephalopathy: effects of eradication. J Hepatol 1999;30:260–264.
[PubMed]
https://doi.org/10.1016%2FS0168-8278%2899%2980072-5
11.
Blei AT: Hepatic encephalopathy; in Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J (eds): Oxford Textbook of Clinical Hepatology, ed 2. Oxford, Oxford Medical, 1999, pp 765–783.
12.
Ahboucha S, Butterworth RF: Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 2004;19:331–343.
[PubMed]
https://doi.org/10.1023%2FB%3AMEBR.0000043979.58915.41
13.
Córdoba J, Sanpedro F, Alonso J, Rovira A: 1H-magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002;17:415–429.
[PubMed]
https://doi.org/10.1023%2FA%3A1021926405944
14.
Clemmesen JO, Larsen FS, Kondrup J, Hansen BE, Ott P: Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648–653.
[PubMed]
https://doi.org/10.1002%2Fhep.510290309
15.
Butterworth RF: Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003;39:278–285.
[PubMed]
https://doi.org/10.1016%2FS0168-8278%2803%2900267-8
16.
Conn HO, Leevy CM, Vhlacevic ZR, Rodgers JB, Maddrey WB, Seeff L et al: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology 1977;72:573–583.
[PubMed]
17.
Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V et al: Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890–895.
[PubMed]
https://doi.org/10.1016%2FS0168-8278%2899%2980144-5
18.
Vaquero J, Chung C, Cahill ME, Blei AT: Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003;23:259–269.
[PubMed]
https://doi.org/10.1055%2Fs-2003-42644
19.
Shawcross DL, Davies NA, Williams R, Jalan R: Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247–254.
[PubMed]
https://doi.org/10.1016%2Fj.jhep.2003.10.016
20.
Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R: The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734–739.
[PubMed]
https://doi.org/10.1053%2Fjhep.2000.17687
21.
Blanc P, Daurès JP, Liautard J, Buttigieg R, Desprez D, Pageaux G et al: Association lactulose-néomycine versus placebo dans le traitement de l’encéphalopathie hépatique aiguë. Résultats d’un essai contrôlé randomisé. Gastroentérol Clin Biol 1994;18:1063–1068.
22.
Scarpignato C, Pelosini, I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36–66.
[PubMed]
https://doi.org/10.1159%2F000081990
23.
Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M: Management of hepatic encephalopathy; role of rifaximin. Chemotherapy 2005;51(suppl 1):90–95.
24.
Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046–1051.
[PubMed]
https://doi.org/10.1136%2Fbmj.38048.506134.EE
25.
Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F: Normal diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38–43.
[PubMed]
https://doi.org/10.1016%2Fj.jhep.2004.03.023
26.
Blei AT, Córdoba J: Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968–1976.
27.
García-Tsao G: Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353–372.
[PubMed]
https://doi.org/10.1016%2Fj.bpg.2003.10.005
28.
Kircheis G, Wettstein M, Dahl S, Hausinger D: Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002;17:453–462.
[PubMed]
https://doi.org/10.1023%2FA%3A1021934607762
29.
Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M: Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084–1092.
[PubMed]
https://doi.org/10.1002%2Fhep.510230523
30.
Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomised trial. Hepatology 1992;16:138–144.
[PubMed]
https://doi.org/10.1016%2FS0168-8278%2805%2980106-0
31.
Als-Nielsen B, Kjaergard LL, Gluud C: Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001;4:CD 002798.
32.
Als-Nielsen B, Gluud L, Gluud C: Dopaminergic agonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004;4:CD003047.
33.
Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C: Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003;2:CD001939.
34.
Jalan R, Sen S, Williams R: Prospects for extracorporeal liver support. Gut 2004;53:890–898.
[PubMed]
https://doi.org/10.1136%2Fgut.2003.024919
35.
Hassanein T, Tofteng F, Brown RS Jr, McGuire BM, Lynch P, Mehta R et al: Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized multicenter trial. Hepatology 2004;40 (suppl 1):726A–727A.
36.
Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660–667.
[PubMed]
https://doi.org/10.1097%2F01.sla.0000124298.74199.e5
37.
Samuel D, Ichai P, Feray C, Saliba F, Azoulay D, Arulnaden JL et al: Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73:257– 264.
[PubMed]
https://doi.org/10.1097%2F00007890-200201270-00019
38.
Kjaergard LL, Liu J, Als-Nielsen B, Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217–222.
[PubMed]
https://doi.org/10.1001%2Fjama.289.2.217
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2006
You do not currently have access to this content.